ライフサイエンスコーパス: latanoprost

1 % KL, and 6.6 +/- 0.6 mm Hg (20%) for 0.005% latanoprost.

2 , greater than the effect produced by 0.005% latanoprost.

3 d further increases after exposure to 200 nM latanoprost.

4 low that occurs after topical treatment with latanoprost.

5 eral outflow facility observed after topical latanoprost.

6 was noted 2 hours after treatment with 0.01% latanoprost.

7 veoscleral outflow pathway after exposure to latanoprost.

8 ost FDC, 22.7% for netarsudil, and 24.7% for latanoprost.

9 actions for the class and cardiac events for latanoprost.

10 etarsudil and an additional 1.3-2.5 mm Hg vs latanoprost.

11 m Hg for netarsudil, and 16.7-17.8 mm Hg for latanoprost.

12 gnificantly depending on the manufacturer of latanoprost.

13 to the effect on the mechanism of action of latanoprost.

14 not meet the criterion for noninferiority to latanoprost.

15 r ocular hypertension who were intolerant of latanoprost.

16 3753380, rs6672484, rs11578155) responses to latanoprost.

17 for both concentrations of AR-13324 than for latanoprost.

18 and MMP-1, were related to refractoriness to latanoprost.

19 available and others who switched to generic latanoprost.

20 Transitioning from BAK-containing latanoprost 0.005 % to BAK-free travoprost 0.004 % prese

21 r ocular hypertension who were intolerant of latanoprost 0.005 % were transitioned to receive once-da

22 h a permuted block design, to receive either latanoprost 0.005% (intervention group) or placebo (cont

23 ductions were greater with NCX 470 0.1% than latanoprost 0.005% at all 6 time points and significantl

24 324 ophthalmic solution 0.02% daily (pm), or latanoprost 0.005% daily (pm) for 28 days.

25 Randomization to once-daily netarsudil 0.02%/latanoprost 0.005% FDC (n = 238), netarsudil 0.02% only

26 rsudil/latanoprost FDC, netarsudil 0.02%, or latanoprost 0.005% for up to 12 months.

27 = 238), netarsudil 0.02% only (n = 243), or latanoprost 0.005% only (n = 237).

28 hen compared to the originator Xalatan((R)) (latanoprost 0.005% ophthalmic solution, Pfizer).

29 re treated with a preserved PGA monotherapy (latanoprost 0.005% or bimatoprost 0.03%).

30 Study participants were randomized to either latanoprost 0.005% or placebo eye drops.

31 nts were randomly assigned to treatment with latanoprost 0.005% or placebo.

32 on to treatment with a prostaglandin analog (latanoprost 0.005%) or placebo.

33 ndomized to NCX 470 0.065%, NCX 470 0.1%, or latanoprost 0.005%.

34 prost Polpharma, a generic preservative-free latanoprost 0.05 mg/ml eye drops solution, in lowering I

35 orms of bimatoprost (0.01 or 0.1 microg/mL), latanoprost (0.03 or 0.3 microg/mL), or unoprostone (0.1

36 ere treated with a commercial formulation of latanoprost (0.5 mug/mL) for 24 hours before imaging.

37 l/latanoprost FDC, 53.4%; netarsudil, 41.0%; latanoprost, 14.0%), which led to treatment discontinuat

38 e as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.

39 concentrations of latanoprost compared with latanoprost 50 mug/mL.

40 re -10.13, -9.59, -10.02, and -9.06 mmHg for latanoprost 50, 75, 100, and 125 mug/mL, respectively, a

41 18.6%, 20.8% and 15.9% of subjects receiving latanoprost 50, 75, 100, and 125 mug/mL, respectively.

42 ere randomized to receive an evening dose of latanoprost 50, 75, 100, or 125 mug/mL for 4 weeks.

43 Latanoprost, a prostaglandin F2alpha analogue, reduces I

44 M) > (+/-)-fluprostenol (EC(50) = 10.8 nM) > latanoprost acid (EC(50) = 34.7 nM) > bimatoprost acid (

45 were exposed to increasing concentrations of latanoprost acid (LA, 1 nM to 10 micro M) for 6, 18, and

46 90 and did not vary with 50, 100, or 200 nM latanoprost acid (P = 0.93, ANOVA).

47 (PG)F(2alpha) or to the PGF(2alpha) analogue latanoprost acid alters mRNA for matrix metalloproteinas

48 e cells with the prostaglandin (PG) analogue latanoprost acid alters transcription of mRNA for matrix

49 etermine the neuroprotective properties of a latanoprost acid derivative (ACS67) that donates the gas

50 Addition of latanoprost acid for 24 hours increased expression of MM

51 Addition of 8, 40, and 200 nM latanoprost acid for 24 hours increased MMP-1 mRNA in a

52 RNA from ciliary muscle cultures exposed to latanoprost acid for 24 hours revealed increased MMP-1,

53 M cells were treated with vehicle control or latanoprost acid for 24 hours.

54 ultures were treated with vehicle control or latanoprost acid for 24 hours.

55 Analysis of cultures exposed to 200 nM latanoprost acid for 4, 6, 12, or 24 hours revealed an i

56 The addition of PGF(2alpha) and latanoprost acid increased ERK1/2 activity by 117% +/- 1

57 Exposure of sclera to latanoprost acid increases transscleral permeation by FG

58 PGF(2alpha) and latanoprost acid induce coordinated alterations of MMP g

59 Latanoprost acid induced a dose-dependent increase of MM

60 n organ culture, and exposed to 50 to 200 nM latanoprost acid or vehicle for 3 days.

61 d for 24 hours with medium supplemented with latanoprost acid or vehicle.

62 6 Wilcoxon test) and that exposure to 100 nM latanoprost acid significantly increased mRNA for MMP-9

63 ion of sclera exposed to 50, 100, and 200 nM latanoprost acid was increased by an average of 48% +/-

64 dextran after exposure to 50, 100, or 200 nM latanoprost acid was significantly increased by 42% +/-

65 hours with medium supplemented with PGF(2a), latanoprost acid, or vehicle.

66 The PGF(2alpha)- and latanoprost-acid-induced ERK1/2 activation was blocked b

67 ly and clinically superior to netarsudil and latanoprost across all 9 time points through month 3, wi

68 The effect of latanoprost after a single 0.01% dose was also measured

69 ports were analyzed, predominantly involving latanoprost and bimatoprost, with most patients being el

70 commonly as the initial drug of choice, but latanoprost and brimonidine are now being recommended by

71 However, latanoprost and brimonidine are often given as monothera

72 Concomitant latanoprost and brimonidine demonstrated better efficacy

73 MMP-3 and -10 mRNA after exposure to 100 nM latanoprost and further increases after exposure to 200

74 on, controlled on the unfixed combination of latanoprost and timolol or eligible for dual therapy bei

75 as that induced by bimatoprost and acids of latanoprost and travoprost.

76 Apraclonidine, latanoprost, and pilocarpine had no measurable effect.

77 aqueous humor concentrations of bimatoprost, latanoprost, and their C-1 free acids indicate that lata

78 and vitreous concentrations of bimatoprost, latanoprost, and their C-1 free acids were determined by

79 Bimatoprost, latanoprost, and travoprost are among the most efficacio

80 prostaglandin analogues (PGAs) bimatoprost, latanoprost, and unoprostone.

81 Pharmacologic effects of timolol, latanoprost, and Y-39983 were studied in hypertensive mi

82 after treatment, there was no difference in latanoprost- and PBS-treated eyes.

83 n F2 alpha (PGF2 alpha) and analogs, such as latanoprost, are thought to lower intraocular pressure (

84 entrations of 0.0001%, 0.001%, and 0.01% and latanoprost at 0.005% were studied separately, with a mi

85 th the individual components, netarsudil and latanoprost, at every time point assessed and an ocular

86 e evaluated noninferiority of NCX 470 versus latanoprost, based on IOP reduction from baseline at 8AM

87 bruary 2011) and the 18 months after generic latanoprost became available (July 2011-December 2012).

88 ontinued to use brand-name PGAs once generic latanoprost became available and others who switched to

89 ed glaucoma drug use altogether when generic latanoprost became available.

90 all antiglaucoma interventions when generic latanoprost became available.

91 Patients who used latanoprost binocularly were asked to return bottles to

92 TIMP-2 was unchanged by bimatoprost and latanoprost, but decreased by unoprostone (35% +/- 8%).

93 rost, and their C-1 free acids indicate that latanoprost, but not bimatoprost, is hydrolyzed in the m

94 AR-13324 0.02% was less effective than latanoprost by approximately 1 mmHg in patients with unm

95 Sustained delivery of latanoprost by contact lenses is at least as effective a

96 terations in the aqueous dynamics induced by latanoprost can be measured reproducibly in the mouse an

97 th latanoprost have given no indication that latanoprost causes clinical CME.

98 favoring any of the higher concentrations of latanoprost compared with latanoprost 50 mug/mL.

99 sessed vision preservation in patients given latanoprost compared with those given placebo.

100 xed-dose combination (FDC) of netarsudil and latanoprost, compared with each active component, in red

101 Latanoprost concentration in residual solution was analy

102 The mean +/- SD latanoprost concentration measured in the residual solut

103 No difference in latanoprost concentrations was found between the bottles

104 Bimatoprost and latanoprost did not change MMP-2.

105 (2)-induced toxicity to RGC-5 cells, whereas latanoprost did not.

106 r CLLO, 3 weeks without treatment, 5 days of latanoprost drops, 3 weeks without treatment, and 1 week

107 Latanoprost-eluting low-dose contact lenses (CLLO) and h

108 derations indicate that the concentration of latanoprost expected in the posterior segment of the eye

109 As a first-line treatment, both SLT and latanoprost eye drops are effective in newly diagnosed P

110 ective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops for the treatment of 24-h intraocu

111 However, the latanoprost eye drops may be better in decreasing mean a

112 e 12-month efficacy and safety of netarsudil/latanoprost FDC are reported.

113 hs revealed superior efficacy for netarsudil/latanoprost FDC compared with the individual components,

114 Once-daily netarsudil/latanoprost FDC demonstrated IOP reductions that were st

115 t (AE) was 82.8% (197/238) in the netarsudil/latanoprost FDC group, 78.2% (190/243) in the netarsudil

116 Netarsudil/latanoprost FDC maintained statistically superior IOP lo

117 Netarsudil/latanoprost FDC met the criteria for superiority to each

118 s demonstrated the superiority of netarsudil/latanoprost FDC over its individual active components at

119 with an incidence of 63.0% in the netarsudil/latanoprost FDC treatment group compared with 51.4% in t

120 mHg for latanoprost (P < 0.05 for netarsudil/latanoprost FDC versus each comparator).

121 The safety profile of netarsudil/latanoprost FDC was consistent with its individual compo

122 reatment discontinuation in 7.1% (netarsudil/latanoprost FDC), 4.9% (netarsudil), and 0% (latanoprost

123 P ranged from 14.8-16.2 mm Hg for netarsudil/latanoprost FDC, 17.2-19.0 mm Hg for netarsudil, and 16.

124 nth 12 was 16.2 +/- 0.23 mmHg for netarsudil/latanoprost FDC, 17.9 +/- 0.20 mmHg for netarsudil, and

125 rnal IOP <=15 mm Hg was 43.5% for netarsudil/latanoprost FDC, 22.7% for netarsudil, and 24.7% for lat

126 event was conjunctival hyperemia (netarsudil/latanoprost FDC, 53.4%; netarsudil, 41.0%; latanoprost,

127 randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0.02%, or latanoprost 0.005%

128 Patients treated with latanoprost for open-angle glaucoma or ocular hypertensi

129 r PGF(2alpha), or PhXA85 (the active form of latanoprost) for 1, 2, and 3 days.

130 Four regionally available latanoprost formulations were measured.

131 In contrast, 10 nM latanoprost free acid and fluprostenol caused membrane d

132 metabolite M1, trans-unoprostone isopropyl, latanoprost free acid, and fluprostenol were studied on

133 eated for 9 days with 10 microg/mL of either latanoprost (free acid) or prostaglandin F(2alpha) ethan

134 Latanoprost-free acid (LFA)-treated NTM cells were analy

135 mm Hg (4.0) in 231 patients assessed in the latanoprost group and 0.9 mm Hg (3.8) in 230 patients as

136 s 19.6 mm Hg (SD 4.6) in 258 patients in the latanoprost group and 20.1 mm Hg (4.8) in 258 controls.

137 sed mean 24-h IOP and peak IOP, although the latanoprost group effect was more potent when compared t

138 The latanoprost group had a more pronounced reduction in IOP

139 Compared with the SLT group, the latanoprost group had a significant and stable decrease

140 preservation was significantly longer in the latanoprost group than in the placebo group: adjusted ha

141 netarsudil group, and 54.0% (128/237) in the latanoprost group.

142 .4% in the netarsudil group and 21.9% in the latanoprost group.

143 18.7 mmHg in the AR-13324 0.01%, 0.02%, and latanoprost groups, respectively, representing a decreas

144 Latanoprost had no effect on IOP in the homozygous FP kn

145 In the UKGTS, treatment with latanoprost halved VF deterioration risk.

146 linical trials and experimental studies with latanoprost have given no indication that latanoprost ca

147 cular edema (CME) in eyes being treated with latanoprost have led to concern regarding a possible cau

148 has been associated with a poor response to latanoprost in a healthy Japanese population.

149 was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time po

150 ndicate that the early hypotensive effect of latanoprost in the mouse eye is associated with a signif

151 a crucial role in the early IOP response to latanoprost in the mouse eye.

152 ) or increase outflow facility (pilocarpine, latanoprost) in primates and humans lowered steady state

153 search, from the marketing of the first PGA, latanoprost, in 1995 to the present.

154 Latanoprost increased MMP-1 (in four of five cultures),

155 Latanoprost increased MMP-3 (in three of five cultures),

156 Bimatoprost and latanoprost increased MMP-9 activity by 75% +/- 27% and

157 The array results also showed that latanoprost induced dose-dependent increases in the expr

158 ted changes could be expected to mediate the latanoprost-induced alteration of ECM in the ciliary bod

159 r topical treatment with 0.00015% or 0.0025% latanoprost, IOP increased by as much as 11% +/- 7%.

160 Latanoprost is a commonly used antiglaucomatous drug, an

161 too low to have a pharmacologic effect, and latanoprost is not known to exhibit vasoactive or inflam

162 oprost (isopropyl ester; EC(50) = 89.1 nM) > latanoprost (isopropyl ester; EC(50) = 778 nM) > bimatop

163 re the ocular hypotensive effects of 15-keto latanoprost (KL) with the commercial preparation of lata

164 Pilocarpine and latanoprost, known to enhance aqueous humor outflow in h

165 sure (IOP), is managed with medications like latanoprost (LAT), a prostaglandin analogue, to enhance

166 The reduction of IOP after latanoprost measurement was calculated by the comparison

167 nonrefrigerated storage, and those who used latanoprost monocularly were asked to return used bottle

168 l fixed combination was equal in efficacy to latanoprost monotherapy, timolol and unoprostone concomi

169 demonstrated modest additional efficacy over latanoprost monotherapy.

170 ncreases in TIMP-1 mRNA levels, as seen with latanoprost (n = 5).

171 latanoprost FDC), 4.9% (netarsudil), and 0% (latanoprost) of patients.

172 eral studies have investigated the effect of latanoprost on intraocular pressure (IOP).

173 r of TIMPs may explain the limited effect of latanoprost on TM outflow.

174 In an eye clinic setting, latanoprost ophthalmic solution 0.005% remains stable af

175 IOP-lowering effect of CLLO, CLHI, or daily latanoprost ophthalmic solution in the same monkeys.

176 CLHI demonstrated greater IOP reduction than latanoprost ophthalmic solution on day 3 (P = 0.001) and

177 Latanoprost ophthalmic solution resulted in IOP reductio

178 c solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-a

179 at least as effective as delivery with daily latanoprost ophthalmic solution.

180 tion of 0.00015%, 0.0006%, 0.0025%, or 0.01% latanoprost or vehicle (phosphate-buffered saline [PBS])

181 ts receiving a topical prostaglandin analog (latanoprost) or placebo eye drops in UKGTS.

182 sed on previous use of any PGA, any non-PGA, latanoprost, or travoprost monotherapies.

183 g for netarsudil, and 17.6 +/- 0.18 mmHg for latanoprost (P < 0.05 for netarsudil/latanoprost FDC ver

184 gnificant in eyes receiving 0.0025% or 0.01% latanoprost (P < 0.05, Student-Newman-Keuls test) and th

185 Compared with persons switching to generic latanoprost, patients who continued taking brand name PG

186 Latanoprost Polpharma was shown to be non-inferior to Xa

187 clinical trial, we evaluated the efficacy of Latanoprost Polpharma, a generic preservative-free latan

188 Latanoprost Polpharma, being preservative-free, also avo

189 (CLHI) were produced by encapsulating a thin latanoprost-polymer film within the periphery of a metha

190 : brimonidine tartrate, dorzolamide-timolol, latanoprost, prednisolone acetate, and moxifloxacin.

191 trations of KL and a 0.005% concentration of latanoprost produced significant (P < 0.05) reductions i

192 Latanoprost reduced IOP by increasing C by 0.009 +/- 0.0

193 In contrast, latanoprost reduced IOP in the treated eye of the hetero

194 Treatment with latanoprost reduced the HR, for VF deterioration by 58%

195 r further determining the mechanism by which latanoprost reduces IOP and alters outflow facility.

196 Latanoprost reduces mouse IOP in a dose-dependent manner

197 the PTGFR and MMP-1 genes may determine the latanoprost response in a white European Spanish populat

198 This study identified 5 SNPs related to the latanoprost response; 1 SNP, rs3753380, already has been

199 sis of CARS/TPAF images of hTMC treated with latanoprost revealed multiple intracellular lipid membra

200 Contrary to the expected result, latanoprost seems to have a significant effect on TM cel

201 18 months before the introduction of generic latanoprost (September 2009-February 2011) and the 18 mo

202 Both SLT and latanoprost significantly decreased mean 24-h IOP and pe

203 cyclobutyl derivative is more efficient than Latanoprost, the most widely used glaucoma drug.

204 ect of bimatoprost and the fixed combination latanoprost-timolol (LTFC) on 24-hour systolic (SBP) and

205 The latanoprost-timolol fixed combination is available in ma

206 The latanoprost-timolol fixed combination provided greater e

207 te occasions, 2 hours after a 200-ng dose of latanoprost to the right eye of homozygous (n = 9) and h

208 MMP-9 is present after latanoprost treatment and may also mediate ECM changes.

209 for MMP-1, -3, -17, and -24 is increased by latanoprost treatment.

210 MMP-9 was present after latanoprost treatment.

211 the genes for MMP-3 and -17 is increased by latanoprost treatment.

212 in ocular biometrics and AHD with timolol or latanoprost treatment.

213 pen-angle glaucoma were allocated to receive latanoprost (treatment) or placebo; the observation peri

214 Bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester, and their resp

215 ts of a possible association between CME and latanoprost use must be given serious consideration, and

216 those treated with higher concentrations of latanoprost versus those receiving 50 mug/mL.

217 A single 200-ng (4 microL) dose of latanoprost was applied to one eye 2 hours before measur

218 rse events were observed within the class as latanoprost was linked to conditions like angina pectori

219 ACS67, its sulfurated moiety (ACS1), and latanoprost were tested for both their toxicity and abil

220 All doses of latanoprost were well tolerated.

221 VEGF, ranibizumab, bevacizumab, micelles and latanoprost, were the latest high-frequency keywords, in

222 ly used as pharmaceuticals and some, such as latanoprost, which is used to treat glaucoma, have becom

223 ng effects of three higher concentrations of latanoprost with the commercially available concentratio

224 rost (KL) with the commercial preparation of latanoprost (Xalatan; Pfizer, New York, NY) in monkey ey

225 ne [Simbrinza; Alcon Laboratories Inc.], and latanoprost [Xalatan; Pfizer, Inc., New York, NY]).